Literature DB >> 32598260

Obesity and Gestational Diabetes in Pregnant Care and Clinical Practice.

José Andrés Poblete1, Pablo Olmos2.   

Abstract

Obesity and Gestational Diabetes Mellitus (GDM) are the most frequent pathologies affecting mothers and offspring during pregnancy. Both conditions have shown a sustained increase in their prevalence in recent years, and they worsen the outcome of pregnancy and the long-term health of mothers. Obesity increases the risk of GDM and pre-eclampsia during pregnancy and elevates the risk of developing metabolic syndrome in later life. Offspring of obese mothers have an increased risk of obstetric morbidity and mortality and, consistent with the developmental origins of health and disease, a long term risk of childhood obesity and metabolic dysfunction. On the other hand, GDM also increases the risk of pre-eclampsia, caesarean section, and up to 50% of women will develop type 2 diabetes later in life. From a fetal point of view, it increases the risk of macrosomia, large-for-gestational-age fetuses, shoulder dystocia and birth trauma. The insulin resistance and inflammatory mediators released by a hypoxic trophoblast are mainly responsible for the poor pregnancy outcome in obese or GDM patients. The adequate management of both pathologies includes modifications in the diet and physical activity. Drug therapy should be considered when medical nutrition therapy and moderate physical activity fail to achieve treatment goals. The antenatal prediction of macrosomia is a challenge for physicians. The timing and the route of delivery should consider adequate metabolic control, gestational age, and optimal conditions for a vaginal birth. The best management of these pathologies includes pre-conception planning to reduce the risks during pregnancy and improve the quality of life of these patients. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Obesity; gestational diabetes mellitus; pregnancy; pregnant care; risks; treatment

Mesh:

Year:  2021        PMID: 32598260     DOI: 10.2174/1570161118666200628142353

Source DB:  PubMed          Journal:  Curr Vasc Pharmacol        ISSN: 1570-1611            Impact factor:   2.719


  5 in total

1.  Downregulation of lncRNA USP2‑AS1 in the placentas of pregnant women with non‑diabetic fetal macrosomia promotes trophoblast cell proliferation.

Authors:  Yiwen Lu; Qiuqin Tang; Shanshan Yang; Yuting Cheng; Mei Li; Dan Guo; Ziqiang Fu; Hua Jiang; Wei Wu
Journal:  Mol Med Rep       Date:  2022-06-08       Impact factor: 3.423

2.  Effects of Early Nursing Monitoring on Pregnancy Outcomes of Pregnant Women with Gestational Diabetes Mellitus under Internet of Things.

Authors:  Linlin Lu; Tinglan Huang
Journal:  Comput Math Methods Med       Date:  2022-06-01       Impact factor: 2.809

3.  Relationship between gestational body mass index change and the risk of gestational diabetes mellitus: a community-based retrospective study of 41,845 pregnant women.

Authors:  Shuang Zhang; Huikun Liu; Nan Li; Wei Dong; Weiqin Li; Leishen Wang; Yu Zhang; Yingzi Yang; Junhong Leng
Journal:  BMC Pregnancy Childbirth       Date:  2022-04-19       Impact factor: 3.105

4.  Delivery, maternal and neonatal outcomes in nulliparous women with gestational diabetes undergoing epidural labour analgesia: a propensity score-matched analysis.

Authors:  Yu Chen; Xin Ye; Han Wu; Xueling Yuan; Xiaofang Yu; Huanghui Wu; Xiaodan Wu; Yanqing Chen
Journal:  BMJ Open       Date:  2022-07-29       Impact factor: 3.006

5.  Trimester-Specific Serum Fructosamine in Association with Abdominal Adiposity, Insulin Resistance, and Inflammation in Healthy Pregnant Individuals.

Authors:  Emilie Bernier; Amélie Lachance; Anne-Sophie Plante; Patricia Lemieux; Karim Mourabit Amari; S John Weisnagel; Claudia Gagnon; Andréanne Michaud; André Tchernof; Anne-Sophie Morisset
Journal:  Nutrients       Date:  2022-09-27       Impact factor: 6.706

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.